News
Keyword Search
08/10/23
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
08/04/23
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
08/01/23
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
07/18/23
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
05/11/23
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
03/30/23
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
03/30/23
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
02/13/23
Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial
01/09/23
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors